Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

1.350 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 1.350
Bid (Size) 1.290 (6)
Ask (Size) 1.500 (5)
Prev. Close 1.350
Today's Range 1.350 - 1.350
52wk Range 1.200 - 43.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Altamira Therapeutics’ SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model
Via ACCESSWIRE
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of... 
Via Benzinga

Performance

YTD
-74.04%
-74.04%
1 Month
-45.34%
-45.34%
3 Month
-66.25%
-66.25%
6 Month
-80.37%
-80.37%
1 Year
-93.16%
-93.16%

More News

Read More
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
Via Benzinga
Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties
Via Spotlight Growth
Dow Surges Over 100 Points; US Services PMI Rises In February
Via Benzinga
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Via ACCESSWIRE
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing
Via ACCESSWIRE
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
Via ACCESSWIRE
Dow Gains Over 100 Points; Eastern Bankshares Shares Drop After Q4 Results
Via Benzinga
Why Applied UV Shares Are Trading Higher By 46%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
US Stocks Higher; Dow Rises 150 Points
Via Benzinga
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via Globe NewsWire
Dow Rises 80 Points; Altamira Therapeutics Shares Plunge
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast
Via Benzinga
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics Provides Year-End 2022 Business Update
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.